#United States #New York #Class Action #Gross Law Firm #aTyr Pharma

Important Investor Alert: Class Action Lawsuit Against aTyr Pharma

The Gross Law Firm has recently issued a significant announcement directed at shareholders of aTyr Pharma, Inc. (NASDAQ: ATYR). For individuals who purchased shares of ATYR within the specified class period, there are crucial steps to take, particularly in light of the lawsuit proceedings.

Class Period and Registration

The class action includes investors who bought shares between November 7, 2024, and September 12, 2025. Shareholders who fit these criteria are strongly encouraged to reach out to the Gross Law Firm concerning the possibility of being appointed as lead plaintiff for this case. It's essential to note that interested shareholders do not need to hold the lead plaintiff position to be eligible for recovery.

Allegations Against aTyr Pharma

The lawsuit is based on serious allegations claiming that executives at aTyr Pharma provided investors with excessively optimistic statements. The complaint details how misleading assertions were made about the drug Efzofitimod, notably regarding its efficacy and the potential for patients to completely reduce their steroid usage. Everything changed dramatically on September 15, 2025, when aTyr disclosed that its EFZO-FIT study had not met its primary endpoint requirement, which resulted in stock prices plummeting from $6.03 to $1.02 in just one day—an 83.2% drop.

This new information came to light during an investor call, where the company's management confirmed that they would engage with the FDA to figure out the next steps following these disappointing results.

Immediate Actions for Shareholders

The deadline for shareholders to register for this class action is December 8, 2025. Delaying could jeopardize potential recovery options related to this lawsuit. Interested concerned investors should register their information on the Gross Law Firm's website to stay updated through their monitoring software related to the case.

Next Steps for Interested Investors

Once registered, shareholders will receive ongoing status updates throughout the legal proceedings. The Gross Law Firm emphasizes there are no financial commitments or obligations for participants—the goal is to advocate for shareholders who have suffered losses due to the alleged deceptive practices of aTyr Pharma.

Why Choose Gross Law Firm?

The Gross Law Firm is widely recognized as a leading class action law firm dedicated to safeguarding investors' rights. With a mission committed to protecting shareholders impacted by fraudulent and illegal business conduct, the firm aims to hold companies accountable to responsible business practices and good corporate citizenship. Investors can trust that Gross Law Firm will strive for the best possible recovery for those affected by misleading actions from companies like aTyr Pharma.

For additional information or to take immediate action, investors should consult with the Gross Law Firm at:

• - Contact: [email protected]
• - Phone: 646-453-8903
• - Office Address: 15 West 38th Street, 12th Floor, New York, NY 10018.

By acting promptly, shareholders can better secure their interests and potentially recover losses incurred during the tumultuous period affecting aTyr Pharma.